Related references
Note: Only part of the references are listed.Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies
Shumei Kato et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Martin J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
Shumei Kato et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Jennifer J. Wheler et al.
CANCER RESEARCH (2016)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
An overview of targeted cancer therapy
Viswanadha Vijaya Padma
BIOMEDICINE-TAIWAN (2015)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
High drug attrition rates-where are we going wrong?
Lisa Hutchinson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Share Paper
